Compare Globus Medical Inc. Class A Common Stock (GMED) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while YieldMax MSTR Option Income Strategy ETF trades at $14.25 (market cap $1.14B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 9× YieldMax MSTR Option Income Strategy ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and YieldMax MSTR Option Income Strategy ETF for 31 Days on average.
| GMED | MSTY | |
|---|---|---|
Market Cap | $10.25B | $1.14B |
Volume | 1,108,124 | 1,611,783 |
Sector | Health | Income / Options Overlay |
52-Week High | $96.82 | $63.60 |
52-Week Low | $58.33 | $11.55 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MSTY trades at $15.52, down 0.13% on the day, with a bearish technical outlook as moving averages signal selling pressure. The ETF's high distribution rate, exceeding 100% annualized, is a key feature but has coincided with significant NAV erosion, as noted in recent financial media. Recent weekly dividend announcements from YieldMax highlight the income focus, but underlying asset volatility remains a concern.
The outlook is cautious; while the high yield is attractive for income-seeking investors, it comes with substantial risk of principal depletion. Analyst sentiment is mixed, balancing the tactical income opportunity against structural concerns about the fund's long-term sustainability in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
